Jodie Sasaki
Dermatology · Renton, WANPI 1902251457
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Dermavant Sciences, Inc. at 41.7% of the total. Reporting peaked in 2024 at $3,750 and has fallen 96.1% since, to $146 in 2025.
Across 83 payments — averaging $70.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dermavant Sciences, Inc.$2K
- AbbVie$713
- Sanofi$515
- Pfizer$421
- Regeneron Healthcare Solutions, Inc.$397
- Galderma Laboratories, L.p.$341
- plus $1K from 10 others
What the payments were for
- Consulting fees$2,40041%
- Food & beverage$3,40358%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dermavant Sciences, Inc. | 2 | $2,452 |
| AbbVie | 17 | $713 |
| Sanofi | 13 | $515 |
| Pfizer | 6 | $421 |
| Regeneron Healthcare Solutions, Inc. | 8 | $397 |
| Galderma Laboratories, L.p. | 5 | $341 |
| Arcutis Biotherapeutics, Inc. | 6 | $272 |
| Lilly USA, LLC | 8 | $238 |
| E.r. Squibb & Sons, L.L.C. | 6 | $164 |
| Amgen | 3 | $85 |
| Incyte Corporation | 3 | $76 |
| Organon | 1 | $75 |
| UCB, Inc. | 2 | $65 |
| Sun Pharmaceutical Industries Inc. | 1 | $30 |
| Revance Therapeutics, Inc. | 1 | $24 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,887 in reported general payments places this provider in the 80th percentile of 323 dermatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 22 | $82,492 |
| Tacrolimus | 44 | $11,116 |
| Fluorouracil | 17 | $1,095 |
| Ketoconazole | 51 | $764 |
| ValacyclovirValacyclovir Hcl | 23 | $761 |
| Clobetasol Propionate | 14 | $742 |
| Desonide | 17 | $724 |
| Triamcinolone Acetonide | 68 | $514 |
| Mupirocin | 39 | $267 |
| Cephalexin | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Renton
- Erica LinnellRenton$6K
- Clive LiuBellevue$2.9M
- Vivian ShiSeattle$971K
- William WerschlerSpokane$948K
- Daniel LevyBonney Lake$541K
- Daniel SugaiBellevue$302K
- Ting-Lin YangBellingham$124K
- James CollyerSeattle$115K
- Cameron ChesnutSpokane$93K
- Alison YoungSeattle$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.